WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels 2024

ATC codeATC level name
A01AB53chlorhexidine and cetylpyridinium
A02BC51omeprazole, combinations
A02BD17vonoprazan and amoxicillin
A02BX16irsogladine
A05AA05ursodoxicoltaurine
A05AX06elafibranor
A07FA03escherichia coli
A10AE07insulin icodec
A10BD28metformin and teneligliptin
A10BD29sitagliptin and dapagliflozin
A10BK08bexagliflozin
A10XX01teplizumab
A16AB26eladocagene exuparvovec
A16AB27pabinafusp alfa
A16AX23leriglitazone
B01AC28limaprost
B01AD13apadamtase alfa and cinaxadamtase alfa
B01AF51rivaroxaban and acetylsalicylic acid
B02BD15valoctocogene roxaparvovec
B02BD16etranacogene dezaparvovec
B02BX10concizumab
B05XA19 1)calcium gluconate
B05XA20 2)sodium selenite
B06AX05exagamglogene autotemcel
C01CA28centhaquine
C01CX10omecamtiv mecarbil
C02KN01aprocitentan
C04AX33clazosentan
C05AX06phenylephrine
C05XX01beperminogene perplasmid
C09BX06perindopril, bisoprolol, amlodipine and indapamide
C09BX07zofenopril and nebivolol
C10AB12pemafibrate
C10BX20rosuvastatin and telmisartan
C10BX21rosuvastatin and perindopril
D03AX16beremagene geperpavec
D05AX06roflumilast
D05AX07tapinarof
D11AH10lebrikizumab
D11AH11delgocitinib
D11AH12nemolizumab
G04BD15vibegron
G04BX17sodium salicylate and methenamine
H02AB18vamorolone
H05AA05palopegteriparatide
H05BX06evocalcet
J01DC52cefuroxime and beta-lactamase inhibitor
J01DD58cefixime and beta-lactamase inhibitor
J01DE51cefepime and beta-lactamase inhibitor
J05AE16ensitrelvir
J05AP13ravidasvir
J05AR28stavudine and lamivudine
J07BN05covid-19, virus-like particles
J07BX05respiratory syncytial virus vaccines
J07BX06enterovirus 71 vaccines
L01BC58decitabine, combinations
L01EJ04momelotinib
L01EK04fruquintinib
L01EL04orelabrutinib
L01EL05pirtobrutinib
L01EX26sitravatinib
L01EX27capivasertib
L01FF11sugemalimab
L01FF12serplulimab
L01FF13toripalimab
L01FX24teclistamab
L01FX25mosunetuzumab
L01FX26mirvetuximab soravtansine
L01FX27epcoritamab
L01FX28glofitamab
L01FX29talquetamab
L01FY03prolgolimab and nurulimab
L01XK52niraparib and abiraterone
L01XL08lisocabtagene maraleucel
L01XL09tabelecleucel
L01XL10nadofaragene firadenovec
L01XL11lifileucel
L01XX78navitoclax
L01XX79eflornithine
L01XX80imetelstat
L02BA04elacestrant
L02BX53abiraterone and prednisolone
L03AA19eflapegrastim
L03AB17sampeginterferon beta-1a
L03AX22leniolisib
L04AC24mirikizumab
L04AC25levilimab
L04AE05etrasimod
L04AF08ritlecitinib
L04AG15divozilimab
L04AG16rozanolixizumab
L04AJ06zilucoplan
L04AJ07crovalimab
L04AJ08iptacopan
L04AJ09danicopan
M01AE57naproxen and diphenhydramine
M04AC51colchicine and probenecid
M09AX14givinostat
M09AX15delandistrogene moxeparvovec
N02AD51pentazocine and naloxone
N02AJ22hydrocodone and paracetamol
N02AJ23hydrocodone and ibuprofen
N02BA67magnesium salicylate, combinations excl. psycholeptics
N02CC51sumatriptan and naproxen
N05CJ03daridorexant
N06AX62bupropion and dextromethorphan
N06DX04lecanemab
N06DX05donanemab
N07XX19sodium phenylbutyrate and ursodoxicoltaurine
N07XX21eplontersen
N07XX22tofersen
N07XX23troriluzole
P02BA03arpraziquantel
R03AK15salbutamol and budesonide
S01AA32bacitracin
S01AX24polihexanide
S01BA16difluprednate
S01CA12loteprednol and antiinfectives
S01HA08chloroprocaine
S01XA31pegcetacoplan
V03AB54pralidoxime and atropine
V04CX11lithium chloride
V09IA10technetium (99mTc) trofolastat chloride
1) Parenteral formulations should be classified here. Oral preparations should be classified in A12AA03.
2) Parenteral formulations should be classified here. Oral preparations should be classified in A12CE02.

Last updated: 2023-12-15